Bristol-Myers Squibb P/E Ratio

Bristol-Myers Squibb (BMY) currently reports a P/E ratio of 14.67. That is below the Healthcare sector average of 25.9. Use the charts on this page to explore Bristol-Myers Squibb's P/E ratio history and peer comparisons.

Bristol-Myers Squibb's P/E ratio of 14.67 is lower than the Healthcare sector average of 25.9. That is roughly 43.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Bristol-Myers Squibb's market price to a fundamental measure such as earnings, sales, or book value. At 14.67, BMY can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 14.67, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.9. From there, open related valuation or income-statement pages for Bristol-Myers Squibb, and consider following BMY for alerts when major investors trade the stock.

Bristol-Myers Squibb is classified in the Healthcare sector. On P/E ratio, it currently shows 14.67 versus a sector average near 25.9. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BMY with unrelated industries.